ragistomig (also known as ABL503) — Topline data
2H 2026
Ragistomig1 PD-L1 x 4-1BB bsAb Solid Tumors Ragi + PD-(L)1 NCT04762641 Phase 1b Topline data 2H 2026Source filing
NBP biotech catalysts & pipeline
NOVABRIDGE BIOSCIENCES · Data as of 2026-09-08
Upcoming catalysts
uliledlimab — Topline data
2H 2026
Progression free survival (PFS) data are expected in 2H 2026 from an ongoing randomized Phase 2 trial evaluating uliledlimab + toripalimab compared to pembrolizumab alone or toripalimab alone.Source filing
givastomig — Topline data
Late 2027
We intend to use the net proceeds from the Offering, together with our existing cash and cash equivalents, to fund ongoing clinical development of our pipeline product candidates, including a randomized Phase 2 trial of givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, intended to have sufficient power and size to generate clinically meaningful progression-free survival (PFS) data by end of 2027, and for working capital and other general corporate purposes.Source filing
givastomig — Conference presentation
Oct 25
October 25, 2026: Poster presentation of Phase 1b combination dose expansion data at the European Society for Medical Oncology (ESMO) Congress 2026Source filing